UWC-19 is under clinical development by UWELL Biopharma and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UWC-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UWC-19 is under development for the treatment of advanced relapsed or refractory CD19 positive hematologic malignancies including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B cell non-Hodgkin lymphoma including primary mediastinal large B cell lymphoma (PMBCL), transformation follicular lymphoma (TFL), high grade B-cell lymphoma (HGBCL), mantle cell lymphoma (MANT), burkitt lymphoma (BURK), lymphoblastic lymphoma. The drug candidate is administered through parenteral and intravenous routes. The therapeutic candidate comprises of autologous T lymphocytes genetically-modified to express CD19-targeting chimeric antigen receptor.
For a complete picture of UWC-19’s drug-specific PTSR and LoA scores, buy the report here.